Cargando…
An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment
SIMPLE SUMMARY: One of the important efforts in the treatment of cancers is to achieve targeted drug delivery by nanocarriers to be more effective and reduce adverse effects. However, due to the adverse responses of nanocarriers in clinical trials due to the very weak EPR effects, doubts have been r...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220781/ https://www.ncbi.nlm.nih.gov/pubmed/35740534 http://dx.doi.org/10.3390/cancers14122868 |
_version_ | 1784732453404934144 |
---|---|
author | Sharifi, Majid Cho, William C. Ansariesfahani, Asal Tarharoudi, Rahil Malekisarvar, Hedyeh Sari, Soyar Bloukh, Samir Haj Edis, Zehra Amin, Mohamadreza Gleghorn, Jason P. Hagen, Timo L. M. ten Falahati, Mojtaba |
author_facet | Sharifi, Majid Cho, William C. Ansariesfahani, Asal Tarharoudi, Rahil Malekisarvar, Hedyeh Sari, Soyar Bloukh, Samir Haj Edis, Zehra Amin, Mohamadreza Gleghorn, Jason P. Hagen, Timo L. M. ten Falahati, Mojtaba |
author_sort | Sharifi, Majid |
collection | PubMed |
description | SIMPLE SUMMARY: One of the important efforts in the treatment of cancers is to achieve targeted drug delivery by nanocarriers to be more effective and reduce adverse effects. However, due to the adverse responses of nanocarriers in clinical trials due to the very weak EPR effects, doubts have been raised in this regard. In this study, an attempt has been made to take a critical look at EPR approaches to enable the convergence of previous papers and the EPR critics to reach an appropriate therapeutic path. Although the effectiveness of EPR is highly variable due to the complex microenvironment of the tumor, there is high hope for cancer treatment by describing new strategies to overcome the challenges of EPR effect. Furthermore, in this paper an attempt was made to provide a reliable path for future to develop cancer therapeutics based on EPR effect. ABSTRACT: The enhanced permeability and retention (EPR) effect in cancer treatment is one of the key mechanisms that enables drug accumulation at the tumor site. However, despite a plethora of virus/inorganic/organic-based nanocarriers designed to rely on the EPR effect to effectively target tumors, most have failed in the clinic. It seems that the non-compliance of research activities with clinical trials, goals unrelated to the EPR effect, and lack of awareness of the impact of solid tumor structure and interactions on the performance of drug nanocarriers have intensified this dissatisfaction. As such, the asymmetric growth and structural complexity of solid tumors, physicochemical properties of drug nanocarriers, EPR analytical combination tools, and EPR description goals should be considered to improve EPR-based cancer therapeutics. This review provides valuable insights into the limitations of the EPR effect in therapeutic efficacy and reports crucial perspectives on how the EPR effect can be modulated to improve the therapeutic effects of nanomedicine. |
format | Online Article Text |
id | pubmed-9220781 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92207812022-06-24 An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment Sharifi, Majid Cho, William C. Ansariesfahani, Asal Tarharoudi, Rahil Malekisarvar, Hedyeh Sari, Soyar Bloukh, Samir Haj Edis, Zehra Amin, Mohamadreza Gleghorn, Jason P. Hagen, Timo L. M. ten Falahati, Mojtaba Cancers (Basel) Review SIMPLE SUMMARY: One of the important efforts in the treatment of cancers is to achieve targeted drug delivery by nanocarriers to be more effective and reduce adverse effects. However, due to the adverse responses of nanocarriers in clinical trials due to the very weak EPR effects, doubts have been raised in this regard. In this study, an attempt has been made to take a critical look at EPR approaches to enable the convergence of previous papers and the EPR critics to reach an appropriate therapeutic path. Although the effectiveness of EPR is highly variable due to the complex microenvironment of the tumor, there is high hope for cancer treatment by describing new strategies to overcome the challenges of EPR effect. Furthermore, in this paper an attempt was made to provide a reliable path for future to develop cancer therapeutics based on EPR effect. ABSTRACT: The enhanced permeability and retention (EPR) effect in cancer treatment is one of the key mechanisms that enables drug accumulation at the tumor site. However, despite a plethora of virus/inorganic/organic-based nanocarriers designed to rely on the EPR effect to effectively target tumors, most have failed in the clinic. It seems that the non-compliance of research activities with clinical trials, goals unrelated to the EPR effect, and lack of awareness of the impact of solid tumor structure and interactions on the performance of drug nanocarriers have intensified this dissatisfaction. As such, the asymmetric growth and structural complexity of solid tumors, physicochemical properties of drug nanocarriers, EPR analytical combination tools, and EPR description goals should be considered to improve EPR-based cancer therapeutics. This review provides valuable insights into the limitations of the EPR effect in therapeutic efficacy and reports crucial perspectives on how the EPR effect can be modulated to improve the therapeutic effects of nanomedicine. MDPI 2022-06-10 /pmc/articles/PMC9220781/ /pubmed/35740534 http://dx.doi.org/10.3390/cancers14122868 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sharifi, Majid Cho, William C. Ansariesfahani, Asal Tarharoudi, Rahil Malekisarvar, Hedyeh Sari, Soyar Bloukh, Samir Haj Edis, Zehra Amin, Mohamadreza Gleghorn, Jason P. Hagen, Timo L. M. ten Falahati, Mojtaba An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment |
title | An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment |
title_full | An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment |
title_fullStr | An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment |
title_full_unstemmed | An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment |
title_short | An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment |
title_sort | updated review on epr-based solid tumor targeting nanocarriers for cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220781/ https://www.ncbi.nlm.nih.gov/pubmed/35740534 http://dx.doi.org/10.3390/cancers14122868 |
work_keys_str_mv | AT sharifimajid anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT chowilliamc anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT ansariesfahaniasal anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT tarharoudirahil anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT malekisarvarhedyeh anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT sarisoyar anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT bloukhsamirhaj anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT ediszehra anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT aminmohamadreza anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT gleghornjasonp anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT hagentimolmten anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT falahatimojtaba anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT sharifimajid updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT chowilliamc updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT ansariesfahaniasal updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT tarharoudirahil updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT malekisarvarhedyeh updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT sarisoyar updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT bloukhsamirhaj updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT ediszehra updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT aminmohamadreza updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT gleghornjasonp updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT hagentimolmten updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment AT falahatimojtaba updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment |